Amphastar Pharmaceuticals

Amphstar Pharmaceuticals, Inc.
Public
Traded as
Headquarters Rancho Cucamonga, California, United States
Key people
  • Mary Z. Luo
  • (Chairman of the Board)
  • Jack Yongfeng Zhang
  • (CEO)
Revenue Increase US$ 240.18 million (2017)
Decrease US$ -895 thousand (2017)
Decrease US$ -4.51 million (2017)
Total assets Increase US$ 454.67 million (2017)
Total equity Increase US$ 337.33 million (2017)
Number of employees
 ~290
Website Amphastar.com
Footnotes / references
[1]

Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company.[2] It was incorporated in May 2004 and primarily develops, manufactures and sells inhalation and intranasal products.[3] One of its products is naloxone, a injectable generic drug that treats opioid overdose, and the company was criticized when it doubled the price of the drug from around $20 to $40 in 2015 during the opioid epidemic.[4] In February 2017 the FDA rejected the company's application to market a device that delivers naloxone intranasally.[4] In March 2018, the company won a patent infringement lawsuit brought against it by Momenta Pharmaceuticals and Sandoz Inc in an ongoing antitrust case.[5]

References

  1. ↑ "U.S. SEC: Form 10-K, Amphstar Pharmaceuticals, Inc". U.S. Securities and Exchange Commission. Retrieved June 27, 2018.
  2. ↑ "Amphastar Pharmaceuticals, Inc. (AMPH)". NASDAQ.com. NASDAQ OMX Group. Retrieved 3 January 2016.
  3. ↑ "Profile:Amphastar Pharmaceuticals Inc (AMPH.O)". Reuters.
  4. 1 2 Arsalan, Arif (February 21, 2017). "After steering through a controversy over soaring price of naloxone, FDA rejects Amphastar's intranasal version". Endpoints.
  5. ↑ Tyler, Eleanor (March 21, 2018). "Amphastar Patent Win Boosts Momenta, Sandoz Antitrust Case". Bloomberg. Retrieved March 24, 2018.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.